Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine
Author(s)
Kaur, Kawaljit; Xiong, Jian; Sawant, Nishant; Agarwal, Sanjeev; Hickey, John M; Holland, David A; Mukhopadhyay, Tarit K; Brady, Joseph R; Dalvie, Neil C.; Tracey, Mary Kate; Love, Kerry R.; Love, J. Christopher; Weis, David D; Joshi, Sangeeta B; Volkin, David B; ... Show more Show less
DownloadPublished version (2.639Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
© 2020 The Authors In a companion paper, a two-step developability assessment is presented to rapidly evaluate low-cost formulations (multi-dose, aluminum-adjuvanted) for new subunit vaccine candidates. As a case study, a non-replicating rotavirus (NRRV) recombinant protein antigen P[4] was found to be destabilized by the vaccine preservative thimerosal, and this effect was mitigated by modification of the free cysteine (C173S). In this work, the mechanism(s) of thimerosal-P[4] protein interactions, along with subsequent effects on the P[4] protein's structural integrity, are determined. Reversible complexation of ethylmercury, a thimerosal degradation byproduct, with the single cysteine residue of P[4] protein is demonstrated by intact protein mass analysis and biophysical studies. A working mechanism involving a reversible S-Hg coordinate bond is presented based on the literature. This reaction increased the local backbone flexibility of P[4] within the helical region surrounding the cysteine residue and then caused more global destabilization, both as detected by HX-MS. These effects correlate with changes in antibody-P[4] binding parameters and alterations in P[4] conformational stability due to C173S modification. Epitope mapping by HX-MS demonstrated involvement of the same cysteine-containing helical region of P[4] in antibody-antigen binding. Future formulation challenges to develop low-cost, multi-dose formulations for new recombinant protein vaccine candidates are discussed.
Date issued
2021Department
Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of Chemical EngineeringJournal
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV